The lymphatic regulator SVEP1 in Schlemm‘s canal function– a therapeutic target for glaucoma (C02)

淋巴调节因子 SVEP1 在施莱姆氏管功能中发挥作用，是青光眼的治疗靶标 (C02)

• 批准号: 529571455
• 金额: --
• 依托单位: Klinik und Poliklinik für allgemeine Augenheilkunde
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/529571455?language=en
• 关键词: lymphatic; regulator; SVEP1; Schlemm; canal

Schlemm’s canal (SC) controls intraocular pressure (IOP) by draining the aqueous humour from the eye, with increased IOP being the main risk factor for glaucoma. Medical treatments to lower IOP through targeting SC are lacking. SC resembles a lymphatic vessel, and targeting lymphatic features of this hybrid vessel might provide new treatment options. Recent Genome-wide association studies implicate SVEP 1 as risk factor for glaucoma. We found that SVEP1 is crucial for lymphangiogenesis and that Svep1 deficiency leads to increased IOP and glaucoma in mice. This project aims to describe Svep1+/- mouse models for increased IOP, decipher the mode of SVEP1 action, and to develop a new therapeutic option for glaucoma via recombinant SVEP1 protein.

施累姆氏管（SC）通过从眼睛排出水状液来控制眼内压（IOP），其中增加的IOP是青光眼的主要风险因素。缺乏通过靶向SC降低IOP的药物治疗。SC类似于淋巴管，靶向这种混合血管的淋巴特征可能提供新的治疗选择。最近的全基因组关联研究表明SVEP 1是青光眼的危险因素。我们发现SVEP 1对淋巴管生成至关重要，并且SvEP 1缺乏会导致小鼠IOP升高和青光眼。该项目旨在描述Svep 1 +/-小鼠IOP升高模型，破译SVEP 1作用模式，并通过重组SVEP 1蛋白开发新的青光眼治疗选择。